Transforming technology to accelerate science and improve productivity for the benefit of patients
Existing IT infrastructure, systems and services were constraining ARIAD’s ability to launch a promising new lung cancer drug. We helped ARIAD plan and manage a program to modernize and improve all aspects of IT.
- Identified application gaps and duplications
- Managed the introduction of the new and improved services, infrastructure and technology without any break in services
- ARIAD are continuing their scientific discovery while preparing for the potential launch of a new cancer drug
With increasing demands placed on IT, growing biopharmaceutical company ARIAD was facing intensifying challenges with their existing IT infrastructure, systems and services - constraining their ability to operate and importantly, launch a promising new lung cancer drug.
A new Chief Information Officer engaged us to help plan and manage a program to modernize and improve all aspects of IT. Around the same time, ARIAD management decided to move their offices to a purpose-built, state-of-the-art premises, which would also have the benefit of bringing all their people into a single building.
We started with an application architecture and infrastructure blueprint, which allowed us to understand the current environment, identify application gaps and duplications, and to see which problems were a priority. We also decided on some fundamental changes including moving much of what had been stored and managed in-house to the cloud.
We recommended the latest technology including Microsoft Surface Hubs which allow people to collaborate in real time. We also helped ARIAD to identify, negotiate with, and transition to new suppliers for their IT services.
For ARIAD, we managed the introduction of the new and improved services, infrastructure and technology without any break in services while maintaining their legacy environment. It was important to take a coordinated approach to make sure people would accept changes, adopt different technologies and stick with them. Now that the move is complete and ARIAD are in their new offices, we’re decommissioning their old technology. As a result of the changes, ARIAD are continuing their scientific discovery while preparing for the potential launch of a new cancer drug.